Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious medical conditions. Founded in 1988, it specializes in monoclonal antibody technologies and has a broad pipeline targeting areas such as ophthalmology, oncology, immunology, and infectious diseases. Known for its collaborations and investment in scientific research, Regeneron has contributed significantly to the development of treatments for various diseases.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 3, 2025 | $0.88 | 2025-08-18 | 2025-08-18 |
| June 6, 2025 | $0.88 | 2025-05-20 | 2025-05-20 |
| March 20, 2025 | $0.88 | 2025-02-20 | 2025-02-20 |
Dividends Summary
- Regeneron Pharmaceuticals Inc has issued 3 dividend payments over the past 0 years
- The most recent dividend was paid 34 days ago, on September 3, 2025
- The highest dividend payed out to investors during this period was $0.88 per share
- The average dividend paid during this period was $0.88 per share.
Company News
Despite recent stock price challenges, Moderna and Regeneron show promising potential in biotech and pharmaceutical sectors, with strong pipelines, innovative treatments, and potential for future growth.
Intellia Therapeutics reported positive Phase 1 trial results for its gene editing therapy nex-z, showing sustained transthyretin protein reductions and potential clinical improvements in patients with hereditary ATTR amyloidosis. The company expects to complete Phase 3 trial enrollment in 2026 and potentially file for biologics license by 2028.
The thalassemia treatment market is expected to grow significantly by 2034, driven by novel drug developments, emerging therapies like pyruvate kinase activators, and improved diagnostic technologies. Currently, no approved drugs exist for alpha thalassemia, but several treatments are available for beta thalassemia.
The biotech sector shows potential for significant growth by year-end, driven by anticipated Federal Reserve rate cuts and improving market conditions that could benefit rate-sensitive biotech stocks.
Regeneron Pharmaceuticals reported better-than-expected Q2 results, driven by growth in Eylea HD, Dupixent, and Libtayo. However, Eylea sales declined due to increased competition. The company's pipeline progress was mixed, with a delay in the FDA decision for linvoseltamab and a three-month extension for the Dupixent COPD indication.
